Expired CME Article

Adverse Drug Reactions: Part II

Authors: James M. Wooten, PharmD

Abstract

Pharmacovigilance is the process of identifying, monitoring, and effectively reducing adverse drug reactions. Adverse drug reactions (ADRs) are an important consideration when assessing a patient's health. The proliferation of new pharmaceuticals means that the incidence of ADRs is increasing. The goal for all health care providers must be to minimize the risk of ADRs as much as possible. Steps to achieve this include understanding the pharmacology for all drugs prescribed and proactively assessing and monitoring those patients at greatest risk for developing an ADR. Groups at greatest risk for developing ADRs include the elderly, children, and pregnant patients, as well as others. Pharmacovigilance must be effectively practiced by all health care providers in order to avoid ADRs.

This content is limited to qualifying members.

Existing members, please login first

If you have an existing account please login now to access this article or view purchase options.

Purchase only this article ($25)

Create a free account, then purchase this article to download or access it online for 24 hours.

Purchase an SMJ online subscription ($75)

Create a free account, then purchase a subscription to get complete access to all articles for a full year.

Purchase a membership plan (fees vary)

Premium members can access all articles plus recieve many more benefits. View all membership plans and benefit packages.

References

1. Wooten J. Adverse drug reactions: part I. South Med J 2010;103:1025–1030.
 
2. Gray CL, Gardner C. Adverse drug events in the elderly: an ongoing problem. J Manag Care Pharm 2009;15:568–571.
 
3. Wright RM, Warpula RW. Geriatric pharmacology: safer prescribing for the elderly patient. J Am Pod Med Assoc 2004;94:90–97.
 
 
4. Riedl MA, Cassillas AM. Adverse drug reactions: types and treatment options. Am Fam Physician 2003;68:1781–1790.
 
5. Oberg KC. Adverse drug reactions. Am J Pharm Ed 1999;63:199–204.
 
 
6. Beyth RJ, Short RI. Principles of drug therapy in older patients: rational drug prescribing. Clin Geriatr Med 2002;18:577–592.
 
7. Routledge PA, O'Mahony MS, Woodhouse KW. Adverse drug reactions in elderly patients. 2003;57:121–126.Br J Clin Pharmacol
 
8. Okie S. Safety in numbers-monitoring risk in approved drugs. N Engl J Med 2005;352:1173–1176.
 
 
9. Blanda MP. Pharmacologic issues in geriatric emergency medicine. Emerg Med Clin North Am 2006;24:449–465.
 
10. Fick DM, Cooper JW, Wade WE, et al. Updating the beers criteria for potentially inappropriate medication use in older adults. Arch Intern Med 2003;163:2716–2724.
 
11. American Academy of Pediatrics, 2007. Available at: http://www.aap.org/advocacy/washing/Therapeutics/docs/coalitionbpcaprea.pdf. Accessed on January 29, 2010.
 
 
12. Verhamme K, Bonifazi F, Ceci A, et al. Adverse drug reactions reporting in children. Pharm Policy Law 2009;11:89–99.
 
 
13. Nebeker JR, Barach P, Samore MH. Clarifying adverse drug events: a clinician's guide to terminology, documentation, and reporting. Ann Intern Med 2004;140:795–801.
 
14. Fattahi F, Pourpak Z, Moin M, et al. Adverse drug reactions in hospitalized children in a department of infectious diseases. J Clin Pharmacol 2005;45:1313–1318.
 
 
15. Peterson RG, Turner C. The physician's role and responsibility in reporting adverse drug events in children. Paediatr Child Health 2003;8:213–214.
 
16. Pillans PI. Clinical perspectives in drug safety and adverse drug reactions. Expert Rev Clin Pharmacol 2008;1:695–705.
 
 
17. Larimore WL, Petrie KA. Drug use during pregnancy and lactation. Prim Care 2000;27:35–53.
 
 
18. Rayburn WF, Amanze AC. Prescribing medications safely during pregnancy. Med Clin N Am 2008;92:1227–1237.
 
19. Carson MP, Ehrenthal D. Medical issues from preconception through delivery: a roadmap for the internist. Med Clin N Am 2008;92:1193–1225.
 
20. Eglash A, Montgomery A, Wood J. Breastfeeding. Dis Mon 2008;54:343–411.
 
21. Ritter JM. Communicating about potential drug harms: safety implications for patients. Br J Clin Pharmacol 2009;68:147–148.
 
22. US Food and Drug Administration. Available at: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm071639.pdf. Accessed March 3, 2010.
 
 
23. Gibbs CR, Lip GY, Beevers DG. Angioedema due to ACE inhibitors: increased risk in patients of African origin. Br J Clin Pharmacol 1999;48:861–865.
 
24. Tseng DS, Kwong J, Rezvani F, et al. Angiotensin-converting enzyme-related cough among Chinese-Americans. Am J Med 2010;123:183.e11–183.e15.
 
25. Hart JA. Do adverse drug reactions to cardiovascular medicines differ among ethnic groups? A viewpoint. BMJ 2006;332:1177–1181.
 
 
26. Brown SD Jr, Landry FJ. Recognizing, reporting, and reducing adverse drug reactions. South Med J 2001;94:370–373.
 
27. Alfirevic A, Pirmohamed M. Adverse drug reactions and pharmacogenomics: recent advances. Per Med 2008;5:11–23.
 
 
28. Ingelman-Sundberg M. Pharmacogenomic biomarkers for prediction of severe adverse drug reactions. N Engl J Med 2008;358:637–639.
 
29. Avigan M. Pharmacogenomic biomarkers of susceptibility to adverse drug reactions: just around the corner or pie in the sky? Per Med 2009;6:67–78.
 
 
30. Corrigan OP. A risky business: the detection of adverse drug reactions in clinical trials and post-marketing exercises. Soc Sci Med 2002;55:497–507.
 
31. United States Food and Drug Administration MedWatch Program. Available at: http://www.fda.gov/drugs/guidancecomplianceregulatoryinformation/surveillance/adversedrugeffects/default.htm. Accessed March 3, 2010.
 
 
32. Brewer T, Colditz GA. Postmarketing surveillance and adverse drug reactions: current perspectives and future needs. JAMA 1999;281:824–829.
 
33. Roden DM. An underrecognized challenge in evaluating postmarketing drug safety. Circulation 2005;111:246–248.
 
 
34. Worst Pills. Available at: http://www.worstpills.org/index.cfm. Accessed March 3, 2010.
 
 
35. Wright JM. Why don't we initiate more large simple randomized controlled trials? CMAJ 2003;169:1170–1171.
 
36. US Food and Drug Administration. Drugs. Available at: http://www.fda.gov/Drugs/default.htm. Accessed March 3, 2010.
 
 
37. Adverse event reporting—Why and How? American Pharmacists Association 2008. Available at: https://www.aphanet.org/AM/Template.cfm?Section=Home2&CONTENTID=15795&TEMPLATE=/CM/ContentDisplay.cfm. Accessed March 3, 2010.
 
 
38. Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981;30:239–245.
 
39. US Department of Health and Human Services. Reducing and preventing adverse drug events to decrease hospital costs. Available at: http://www.ahrq.gov/qual/aderia/aderia.htm#ADEsPrevented. Accessed March 3, 2010.
 
 
40. Jha AK, Laguette J, Seger A, et al. Can surveillance systems identify and avert adverse drug events? A prospective evaluation of a commercial application. J Am Med Inform Assoc 2008;15:647–653.
 
41. Brassey J. Electronic resources reviews. J Med Libr Assoc 2007;95:215–225.
 
 
42. Breckenridge A, Woods K, Raine J. Monitoring the safety of licensed medicines. Nat Rev Drug Discov 2005;4:541–537.
 
43. Gandhi TK, Weingart SN, Borus J, et al. Adverse drug events in ambulatory care. N Engl J Med 2003;348:1556–64.